Dexmedetomidine for Cesarean Delivery

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Regional anesthesia has become the anesthetic of choice for cesarean section in most countries; however, some women still prefer general anesthesia techniques. There are many trials for the pharmacological modifications of the sympathetic response to surgery, including opioids, tenoxicam, ketorolac, lidocaine and paracetamol. However, opioid administration to the mother before delivery has adverse neonatal effects. This research is a novel trial on the use of dexmedetomidine for suppression of the hemodynamic and hormonal responses of cesarean delivery.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: King Faisal University
• Treatments: Anesthetics; Dexmedetomidine; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• 80 women aged 18-45 years (ASA physical status II-III)with uncomplicated, singleton pregnancies of at least 36 weeks' gestation scheduled for elective cesarean delivery under general anesthesia.

Exclusion Criteria:

• women with a history of cardiac, liver, or kidney diseases;

• women with allergy to amide local anesthetics;

• women with epilepsy;

• those taking cardiovascular medications;

• those with pregnancy-induced hypertension;

• women with evidence of intrauterine growth restriction or fetal compromise.